N/A N=112 A Cohort Study of Weight Loss and Gliosis
Obesity, Gliosis, Weight-Loss
Primary: Percent Change in Weight From Baseline — -6.1; -21.2; 1.2 percentage change from baseline — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3 Deep Brain Stimulation Effects on Weight Change and Metabolic Rate
Obesity
Primary: Change in Metabolic Rate — 7.6; 18 percentage of increase in REM and SEE
N/A N=20 Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity
Obesity
Primary: Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) — .0468; .0492…
Phase 4 N=61 Neurocognitive Benefits of a Weight Management Program
Overweight and Obesity
Primary: Blood Oxygen Level-dependent (BOLD) Response to High-calorie Foods Cues Minus Neutral Objects in Left Anterior Cingulate Cortex — -0.05; -0.16 percent BOLD signal change
N/A N=27 Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Diabetes · Obesity
Primary: Measure Erythrocyte G6PD Levels in Diabetic vs. Non-diabetic Morbidly Obese Patients Undergoing Laparoscopic Gastric Bypass. — 3.12; 0.67; 22; 13 nM/min/mg — p=<0.05
Phase 2 N=34 Biological Effects of Weight Loss In Older, Obese Women
Obesity · Sarcopenia
Primary: Performance on the 400 Meter Walk — 0.16; 0.02 meters per second — p=<0.05
Phase 3 N=42 Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Hypothalamic Obesity
Primary: Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². — 1.7; 3.5 percent change from baseline — p=0.40
N/A N=57 Insulin-sensitive Obesity: Lessons From Longitudinal Data
Insulin Sensitivity/Resistance · Obesity
Primary: Insulin Sensitivity — 0.0105; -0.0076; 0.0041 micro mol/min/Kg/mU/L/year
N/A N=50 Bariatric Surgery for Morbid Obesity
Obesity · Morbid Obesity
Primary: Size of Adipocytes — 73.4; 99.0; 103.0 µm
N/A N=51 Obesity and Nonalcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Hepatic Insulin Sensitivity Index (HISI) — 0.8; 1.4 [10000/(μmol/min)x(mU/L)] — p=<0.019
N/A N=28 Dopamine and Insulin Resistance
Obesity
Primary: Striatal DRD2 Receptor Binding — 28; 33; 32; 33 ratio — p=<0.05
N/A N=80 Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal
Phase 2 N=10 Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
Obesity · Overweight · Craniopharyngioma
Primary: Body Weight (kg) — -1.4 kg
N/A N=20 Changes in Ectopic Fat Following Surgically Induced Weight Loss
Obesity · Type 2 Diabetes
Primary: Pancreatic and Liver Triglyceride (Fat) Content — 6.44; 2.08 percent
N/A N=51 Effect of Weight Loss on Myocardial Metabolism and Cardiac Relaxation in Obese Adults
Obesity
Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min
N/A N=18 The Effects of Chiropractic in a Population With High Central Adiposity
Abdominal Obesity
Primary: Proportion of Potential Participants Who Are Eligible. — 0.95 Proportion
N/A N=81 Effects of Different Surgical Methods to Treat Obesity
Obesity · Type 2 Diabetes · Insulin Sensitivity
Primary: Insulin Sensitivity at 2 Years — 6.7; 6.6 glucose/kg body weight/min
Phase 1 N=10 Weight Management Program for Patients With First Episode Psychosis
Diet, Healthy · Psychotic Disorders
Primary: Weight — -6; -3; -5; -4 Lbs
N/A N=24 Growth Hormone as a Determinant of Weight Regulation
Obesity
Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL
Phase 2 N=24 Leptin in the Maintenance of Reduced Body Weight
Obesity
Primary: Percent Change From Baseline in Body Weight at 6 Months — 10.2; 12.7 percentage change
N/A N=60 The Association Between Endometriosis, Obesity and nesfatin1
Endometriosis
Primary: Serum Nesfatin 1 — 190; 510 picogram/millilitre — p=0.05
N/A N=5 Sympathetic Activation in Obesity
Obesity · Healthy
Primary: Distribution Volume Ratio (DVR) of [11C]MRB PET Imaging of Peripheral Sympathetic Nervous System — 0.13; -0.025; 0.095; -0.03 DVR
Phase 3 N=49 Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
Parkinson's Disease
Primary: Number of Subjects With Small Bowel Bacterial Overgrowth (SBBO) — 2; 12; 2; 9 participants — p=1.0
N/A N=31 Gastrointestinal Hormonal Regulation of Obesity
Obesity
Primary: Change in Body Weight From Baseline to 12 Months — 1.09; 1.55 lbs
N/A N=5 Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss
Obesity · Weight Loss
Primary: The Primary Outcome Will be the Leptin Levels at Baseline and 8 Weeks — 39.5; 13.4 ng/ml
Phase 4 N=23 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Glucose Intolerance · Overweight and Obesity · Drug Effect
Primary: Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue) — 7.88; 7.67 natural log(arbitrary units)
N/A N=16 The Role of Altered Nutrient Partitioning in Food Reward
Overweight and Obesity
Primary: Change in Preference- Liking — 6.5; 4.5 units on a scale
N/A N=129 Weight Loss Physical Disabilities
Physical Disability
Primary: Weight Change in kg From Baseline to 6-months — -6.23; -8.16 kg
N/A N=26 Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Trifunctional Protein Deficiency
Primary: An Outcome of This Study is the Difference in Percent Body Fat (%BF) Between Subjects With a Long-chain Fatty Acid Oxidation Disorder and Normal Controls. — 31.8; 27.2…
Phase 3 N=44 Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management
Overweight · Obese
Primary: Change in Waist Circumference — -2.3; -6.0; -4.0 cm — p=0.398